EPCAM and neoplasm: When compared to control tumor samples, analyses of CSCs markers in rat tumor specimens showed a dose-dependent decline in ALDH1 expression by 31.5% (p = 0.069) and 43.5% (p < 0.05) vs. controls and a dose-independent decline in the expression of EpCam by 31% (p < 0.01) and 23% (p < 0.05) vs. controls, respectively.